Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020


Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference being held next week in San Francisco. Exelixis' presentation has been scheduled for Tuesday, January 14, 2020 at 7:30 PM EST / 4:30 PM PST.

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery ? all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.


These press releases may also interest you

at 11:02
2024 Annual Meeting of the American College of Clinical Pharmacology® - The Premier Clinical Pharmacology Educational & Scientific Meeting
The American College of Clinical Pharmacology® (ACCP) is pleased to announce its 2024 ACCP Annual Meeting (#2024ACCP) will be held September 8 ? 10, 2024. We encourage you to join us for this transformative educational and scientific event! ACCP...

at 11:01
Breakthrough Study Reveals Somavedic Device's Potential Impact on Wet AMD Patients
Somavedic, a trailblazer in sleep and digital pollution-neutralizing frequency therapy technology, in collaboration with researchers from the Eye Clinic of Jan Evangelista Purkyn? University and Masaryk Hospital in Ústí nad Labem in the Czech...

at 11:00
PCORI announces $150 million in funding for new health research
The Patient-Centered Outcomes Research Institute (PCORI) today announced the approval of funding awards totaling more than $150 million to support new patient-centered comparative clinical effectiveness research (CER) studies, research to strengthen...

at 11:00
Public Advisory - Health Canada warns about multiple unauthorized sexual enhancement products that may pose serious health risks
Health Canada is advising that the following product(s) may pose serious health risks. For more information, including product photos and what you should do, visit these online safety alerts: ?  Unauthorized sexual enhancement products Health Canada...

at 11:00
Excellent Cancer Care, Exclusive Clinical Trials
Every treatment prescribed by a doctor today was once a part of research in a clinical trial. Clinical research is thriving at Thompson Cancer Survival Center....

at 10:59
Majority of Respondents to Second Annual Survey of Health Care Professionals Fall Short of Benchmark for Workplace Safety
According to the second annual Workplace Violence Prevention Training Annual Report for health care ? which provides insight into the state of workplace violence prevention training in health care ? the majority of health care professionals surveyed...

More news about Health...


News published on and distributed by: